
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Akt2 CRISPR Activation Plasmid (h) | sc-400060-ACT | 20 µg | $397.00 | |||
Akt2 CRISPR Activation Plasmid (h2) | sc-400060-ACT-2 | 20 µg | $397.00 |
AKT2 encodes the serine/threonine kinase Akt2, a core effector of PI3K-dependent signaling that couples growth factor stimulation to cellular metabolism, survival, and proliferation. Akt2 phosphorylates substrates that regulate glucose uptake, glycogen synthesis, lipid metabolism, and cell cycle progression, with prominent roles in insulin signaling and mTOR pathway control. In human biology, altered AKT2 activity has been linked to dysregulated metabolic homeostasis and oncogenic signaling circuits that shape cell growth and stress resistance. As a pathway node integrating receptor tyrosine kinase inputs with downstream transcriptional and metabolic programs, AKT2 is widely studied in models of insulin resistance, adipocyte biology, and tumor cell signaling.
Akt2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous AKT2 expression without altering the underlying DNA sequence.
Akt2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the AKT2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the AKT2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Akt2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native AKT2 locus and enabling the study of Akt2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Akt2 pathway restoration in tumor cells with silenced or reduced AKT2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.